The recognition that insulin resistance has a central role in polycystic ovary syndrome has led to new approaches to treatment. While clinical presentations may still be managed symptomatically, there is increasing interest in insulin sensitisers including metformin. Drug treatments do not displace the management of behavioural risk factors to achieve weight loss in women who are overweight or obese. Weight loss leads to improvement in symptoms, and other long-term health benefits.
Introduction
Polycystic ovary syndrome is a heterogeneous condition characterised by hyperandrogenism and anovulation. It presents during a woman's reproductive years as menstrual disturbance, infertility, hirsutism, or acne. Insulin resistance is very common in women with polycystic ovary syndrome. It is also common in women who have a body mass index greater than 30 kg/m 2 .
In polycystic ovary syndrome obesity therefore adds to insulin resistance. These women have an increased prevalence of cardiovascular risk factors and many have the metabolic syndrome. Follow-up studies have shown an earlier onset of type 2 diabetes mellitus. These women are not oestrogen deficient and they may develop endometrial hyperplasia which confers an increased risk of endometrial cancer.
Polycystic ovary syndrome can be diagnosed clinically.
However, it should be considered a diagnosis of exclusion and other endocrine disorders should be considered. These include congenital adrenal hyperplasia, androgen secreting tumours of the ovaries or adrenal glands, Cushing's syndrome, hyperprolactinaemia, thyroid disease and use of exogenous androgens.
Lifestyle interventions aimed at reducing body mass index and improving insulin sensitivity are central to the initial and ongoing management of women with polycystic ovary syndrome. The women need advice about reducing the calories in their diet as well as advice and support in increasing physical activity. Modest weight loss of about 5% of the initial body weight can improve the menstrual cycle and studies confirm improvements in ovulation rates and fertility. Women with polycystic ovary syndrome also need advice on long-term behavioural change to manage their increased risk of cardiovascular disease. Those who smoke should be offered assistance to help them quit. When drug therapies are required, the choice of medication is influenced by whether the patient's main complaint is menstrual irregularity, infertility, acne or hirsutism.
Menstrual problems
In women presenting with menstrual problems, it is important to clarify the diagnosis (including the exclusion of pregnancy) and ask if they need contraception or are planning pregnancy.
For those with oligomenorrhoea who are not planning pregnancy, the combined oral contraceptive pill may be appropriate. However, which combined oral contraceptive pill is best for women with polycystic ovary syndrome is unknown.
Combined contraceptive pill
The combined oral contraceptive pill controls the menstrual problems by establishing regular withdrawal bleeds and reducing menstrual flow. It also reduces hyperandrogenism and long-term use reduces the risk of endometrial cancer.
The combined oral contraceptive pill does not address the pathophysiology of polycystic ovary syndrome or improve the insulin resistance that usually underlies the hyperandrogenism.
It has been reported to aggravate insulin resistance in women with polycystic ovary syndrome as well as those without this phenotype. However, in the general population the combined oral contraceptive pill has not been associated with an increased risk of type 2 diabetes mellitus. There is also no convincing evidence of an increased risk of diabetes when the combined oral contraceptive pill is used in women with polycystic ovary syndrome.
Of concern is the long-term risk of cardiovascular disease in women with polycystic ovary syndrome. At present, there is no evidence to suggest that they experience more cardiovascular events while taking the combined oral contraceptive pill. Liver function tests should be checked prior to the prescription of cyproterone acetate, and at six-monthly intervals.
Spironolactone should not be used in patients with renal impairment, and renal and potassium status should be checked before therapy and after three months. hirsutism. However, they are not in general use in Australia.
Flutamide may cause hepatotoxicity, while finasteride is teratogenic.
Management of long-term risks
Insulin resistance is important in the development of the metabolic syndrome and is associated with an increased risk of cardiovascular disease. There are no long-term clinical studies to assess the benefit of metformin in reducing adverse cardiovascular outcomes in women with polycystic ovary syndrome. 5 However, the findings of the Diabetes Prevention
Program Research Group (which found lifestyle changes were more effective than metformin in reducing the incidence of type 2 diabetes in people at high risk) suggest that clinicians should persist in working with their patients to achieve lifestyle changes that will reduce body mass and improve insulin sensitivity. 6
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may have been little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. The infused agalsidase is taken up by endothelial lysosomes and has an elimination half-life of 45-100 minutes. As agalsidase is broken down by peptide hydrolysis, impaired liver or renal function may have little effect on clearance.
Agalsidase beta
As the incidence of Fabry's disease is less than 1 in 100 000 births, clinical trials involve only a few patients. In a placebocontrolled trial 29 adult patients were treated with agalsidase beta for 20 weeks. After 11 infusions, 69% of this group had no microvascular endothelial deposits of globotriaosylceramide in more than 50% of the capillaries seen on renal biopsy.
Deposits were also significantly reduced in the skin and the heart. There was also a significant reduction in the amount of globotriaosylceramide in the urine. 1 
